2011 International Nuclear Atlantic Conference - INAC 2011 Belo Horizonte,MG, , October 24-28, 2011 ASSOCIAÇÃO BRASILEIRA DE ENERGIA NUCLEAR - ABEN ISBN: 978-85-99141-04-5

CALCIUM PHOSPHATE HOLMIUM-166 CERAMIC TO ADDITION IN BONE CEMENT: SYNTHESIS AND CHARACTERIZATION

Blanda A. Donanzam 1, Tarcísio P. R. Campos 1, Ilza Dalmázio 2 and Eduardo S. Valente 2

1 Departamento de Engenharia Nuclear – Escola de Engenharia Universidade do Federal de Minas Gerais Av. Antônio Carlos, 6627, PCA1 31270-901 Belo Horizonte, MG [email protected] , [email protected]

2 Centro de Desenvolvimento de Tecnologia Nuclear (CDTN / CNEN - MG) Av. Antônio Carlos, 6627 31270-901 Belo Horizonte, MG [email protected] , [email protected]

ABSTRACT

Spine metastases are a common and painful complication of cancer. The treatment often consists of bone cement injection (vertebroplasty or kyphoplasty) within vertebral body for vertebrae stabilization, followed by external beam radiation therapy. Recently, researchers introduced the concept of radioactive bone cement for spine tumors therapy. Then, investigations about bioactive and radioactive materials became interesting. In this study, we present the synthesis of phosphate incorporated holmium (CaP-Ho) via sol-gel technique, and its characterization by XRD, FT-IR, NA and SEM. Results showed a multiphasic bioceramic composed mainly of hydroxyapatite, β-tricalcium phosphate, holmium phosphate and traces of calcium pyrophosphate. Furthermore, the nuclide Ho-166 was the major radioisotope produced. Despite that, the radioactive bioceramic CaP-166 Ho must be investigated in clinical trials to assure its efficacy and safety on spine tumors treatment.

1. INTRODUCTION

Spinal metastases are a common manifestation of many types of cancer. Specifically, metastatic lesions in the spine have been found in 90%, 74% and 45% of patients who died from prostate, breast and lung cancer, respectively [1]. Vertebral metastases cause pain and, due to the proximity of the spinal cord, can lead to serious neurological complications resulting from vertebral collapse. Treatment must address the tumor itself as well as the structural deficiency it may cause in the bone [2]. The conventional treatment often occurs in two steps, a surgical procedure in which polymethylmethacrylate (PMMA) bone cement is injected into the vertebral body to restore bone strength (vertebroplasty or kyphoplasty), followed by multiple daily radiotherapy sessions to control tumor growth [3].

The most common type of radiotherapy for spinal metastases is external beam radiation therapy (EBRT). Although EBRT effectively delivers radiation to the vertebral body, adjacent radiosensitive tissues such as the spinal cord is also irradiated, often limiting the dose that can be safely delivered to the tumor [4, 5]. Thus, to maximize treatment effectiveness while minimizing collateral damage to normal tissue, EBRT is fractionated into ten daily treatment sessions, inconveniencing patients whose quality of life has already been compromised. Intensity modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) have emerged as improved radiotherapy techniques, but both techniques still irradiate the spinal cord (albeit to a lesser extent), and are expensive [3, 6, 7].

Few years ago, a new therapy modality named radiovertebroplasty, proposed to combine the two steps of the conventional treatment approach into a single procedure utilizing radioactive bone cement, i.e. bone cement mixed with a radionuclide [8]. If effective, this combined approach would integrate radiation therapy and the surgical strength-restoration procedure into a single procedure for treatment. Additionally, by directing radioactive bone cement to the location of the tumor, a beta-emitting radionuclide can be used to create emissions that penetrate only the adjacent bone/tumor, potentially allowing for a higher dose to the target bone and minimal dose to the spinal cord and other normal tissue nearby. Few researchers published his preliminaries investigations about this new technique, therefore more studies is obviously necessary till assure the radiovertebroplasty benefits [3, 9-11].

Polymethylmethacrylate (PMMA) is the material most used as bone cement, it has good mechanical performance and is inert to boby [12]. At the same time, biomaterials based on calcium phosphates ceramics (CaPs) have been extensively investigated as bone substitutes because their similar chemical characteristics originate bioactive properties as osteoconduction and osteointegration [13-17]. There are many kinds of calcium phosphates bioceramics, each one has distinct properties of strength, stability and solubility in physiological environment. They have been explored to applications in bone replacements, coatings on implants, bone cements, including in association with PMMA. Among the existing calcium phosphates, the most interesting ones are hydroxyapatite and tricalcium phosphate [18-19].

Considering that, we suggest the composite PMMA/CaP-beta emitter as a promising radioactive bone cement taking account the interesting properties of its components.

In this work, it was synthesized and characterized calcium phosphate incorporated holmium (CaP-Ho). The radionuclide 166 Ho (half-life 26,8 hours) undergoes beta decay to 166 Er, emits β- particles with mean energy of 665 keV and maximum range in bone of 5,2 mm. 166 Ho can be produced by neutronic activation of 165 Ho (100% ). The radioactive bioceramic CaP-166 Ho when added on PMMA gives rise to a radioactive bone cement. We hope its injection inside the tumor location will stabilize the vertebrae and additionally control the tumor by a local dose deposition.

2. MATERIALS AND METHODS

2.1. Synthesis

Sol-gel route was the choice as synthesis technique by its simplicity, flexibility and low cost. It were produced bioceramics of holmium incorporated calcium phosphate (CaP-Ho) and calcium phosphate (CaP) pure for some comparisons. The starting materials employed in bioceramics synthesis are calcium nitrate tetrahydrate [Ca(NO 3)2.4H 2O], distilled water, phosphoric acid 85% (H3PO 4), and specifically in CaP-Ho, holmium (Ho 2O3) dissolved in nitric acid. The chemicals ratio in CaP were calculated to induce the formation of hydroxyapatite with molar ratio Ca/P= 1,67. While in CaP-Ho, the same chemicals ratio was used except that 10% of calcium atoms were substituted by holmium atoms.

INAC 2011, Belo Horizonte, MG, Brazil.

To prepare the , calcium nitrate was firstly dissolved in distilled water and then the others reagents were added. The sols were stirred in vortex for 10 minutes and placed in a ceramic crucible to age for 24 hours at ambient conditions. Afterward, the solvents were eliminated by drying for 18 hours at 100°C. The gels obtained were calcined in a furnace for 1 hour at 700°C without atmospheric control. At the end of the process a ceramic formation was observed into the crucible. They were powdered with mortar and pestle for future applications in powder form.

2.2. Characterization

2.2.1. X-Ray Diffraction (XRD)

Powder X-ray diffraction (XRD) patterns were recorded with CuK α radiation on a diffractometer (Rigaku, model D/MAX Ultima automatic). The crystalline phases were qualitatively determined from a comparison of the registered patterns with the ICDD powder diffraction file (PDF).

2.2.2. Fourier Transform Infrared Spectroscopy (FTIR)

The characteristics infrared absorptions from functional groups were analyzed on a Fourier- transform infrared spectrometer (Thermo Scientific, model Nicolet 380) with a resolution of 4 cm -1, recorded in the range of 400-4000 cm -1, using KBr pellets.

2.2.3. Neutron Activation (NA)

Neutron activation of bioceramics was performed in TRIGA MARK I IPR-R1 research reactor. Irradiation spent 8 hours under thermal and epithermal neutron flux of 8,0x10 11 e 3,5x10 10 n.cm -2.s -1, respectively. The activity of irradiated material was measured with a dose calibrator (CAPINTEC, model CRC-25R). The gamma spectrum was recorded by a high- purity germanium detector (Camberra, model GC5019) coupled to a multichannel analyzer (Camberra, model DSA 1000) and counting time of 500 seconds.

To determine the elemental concentration in the bioceramic samples it was applied the technique k0-instrumental neutron activation analysis (k 0-INAA) as set up in the Laboratory for Neutron Activation Analysis, CDTN/CNEN [20].

2.2.4. Scanning Electron Microscopy (SEM)

Morfologic characterization was obtained in a scanning electron microscope (FEI, model Quanta 200 FEG).

INAC 2011, Belo Horizonte, MG, Brazil.

3. RESULTS AND DISCUSSION

The XRD patterns of the bioceramics (Fig. 1) detected the existence of several crystalline phases. In CaP (Fig. 1a), the main is hydroxyapatite (HAp), but it was noted traces of . In CaP-Ho (Fig. 1b), the major phases are HAp and β-tricalcium phosphate (β-TCP), the minor phase is holmium phosphate. The holmium incorporation into the bioceramic matrix was accommodated as holmium phosphate and gave rise to a second phase beyond HAp, the β-TCP with molar ratio Ca/P=1,5.

Figure 1. X-ray diffraction patterns (XRD) of (a) CaP and (b) CaP-Ho.

The FTIR spectrum of CaP (Fig. 2a) revealed the typical HAp vibrational modes of 3- -1 - orthophosphate (PO 4 ) at 569, 602, 962, 1045 and 1090 cm , and hydroxyl (OH ) at 631 and -1 4- -1 3572 cm [21,22]. Several pyrophosphate (P2O7 ) peaks at 727, 1157, 1188 and 1211 cm demonstrated the existence of calcium pyrophosphate (Ca 2P2O7) [23-25]. The absorption -1 -1 2- band centered at 1460 cm and the peak at 877 cm are associated to carbonate (CO 3 ) in substitution of orthophosphate in HAp structure, it comes from the atmospheric absorved during the synthesis and generates the carbonated hydroxyapatite type B (CHAp) [26, 27]. Carbonate incorporation in HAp structure is not easy to be detected by XRD, however the calcium oxide observed in CaP diffraction pattern (Fig. 1a) probably came from CHAp decomposition during the thermal treatment [28]. The FTIR spectrum of CaP-Ho (Fig. 2b) exhibited HAp absorption peaks of orthophosphate at 1045 and 1090 cm -1 and small

INAC 2011, Belo Horizonte, MG, Brazil. hydroxyl peaks at 631 and 3572 cm -1. These less intense hydroxyl peaks might be due the decrease in crystallinity or even another phase like β-TCP, previously detected by XRD (Fig. 1b) [26, 29]. The shift of ortophosphate peaks at 569 and 602 cm -1 to 557 and 604 cm -1 is consistent with β-TCP existence. A small peak from pyrophosphate at 727 cm -1 suggests discrete quantities of calcium pyrophosphate. Orthophosphate characteristics vibrations assigned to holmium phosphate were not detected [30]. In both CaP and CaP-Ho the infrared spectrum evidenced HAp as major component corroborating to XRD measurements, but indicated the calcium pyrophosphate presence that was not detected by XRD, and possibly in small concentrations was hidden by more numerous phases.

Figure 2. Infrared spectrum (FTIR) of (a) CaP and (b) CaP-Ho.

After CaP-Ho irradiation, specific activity measured was 12,61 MBq/mg, however this value can be modified with time irradiation and neutron flux (variable with position on reactor). The gamma spectrum obtained from radioactive CaP-Ho (Fig. 3) was useful to evaluate its radiochemical purity. As expected, the gamma spectrometry analysis demonstrates that the highest activity in CaP-Ho is due to 166 Ho radionuclide. The peaks correspond to the energies of gamma radiation emitted by 166 Ho and K-edge X-rays of 166 Er, stable product of 166 Ho. Other expected radionuclides, such as 41 Ca, 45 Ca, 47 Ca, 49 Ca and 32 P have short half-lifes or their precursor nuclides have low neutron capture cross section.

Calcium and holmium concentrations, measured by k 0-INAA, were summarized in Table 1. Phosphorus and oxygen concentrations are not detected due to limitations of the technique. Calcium mass concentration of CaP is 38%, similar to HAp that is 39,9%. Holmium mass concentration in CaP-Ho is 13,7%, and a smaller calcium concentration of 29% is consistent with holmium insertion, a heavier atom.

INAC 2011, Belo Horizonte, MG, Brazil.

Figure 3. Gamma spectrum of activated CaP-Ho (a) in low energy and (b) in high energy.

Table 1. Elemental concentration by employing k0-INAA.

Elemental mass concentration CaP CaP-Ho Calcium 38% (± 1) 29% (± 1) Holmium - 13,7% (± 0,5)

INAC 2011, Belo Horizonte, MG, Brazil.

SEM micrographs revealed the morphologic aspect of the powders. In CaP (Fig. 4a), it is possible to visualize the needle-like nanoparticles of hydroxyapatite, while in CaP-Ho (Fig. 5a) the particles densification are more evident due to calcination process at 700°C. In both bioceramics (Fig. 4b and 5b) the grains have irregular sizes and shapes due to milling process.

Figure 4. SEM micrographs of CaP (a) 25000X and (b) 5000X.

Figure 5. SEM micrographs of CaP-Ho (a) 25000X and (b) 5000X.

INAC 2011, Belo Horizonte, MG, Brazil.

4. CONCLUSIONS

In this work, it was synthesized calcium phosphate incorporated holmium, a promising bioceramic for spine tumors treatments. Results showed a multiphasic bioceramic composed mainly of hydroxyapatite, β-tricalcium phosphate, holmium phosphate and traces of calcium pyrophosphate. Moreover, the nuclide of interest 166 Ho was the major radioactive specimen produced. However, its bioactivity as well as its efficacy on spine tumors therapy must be investigated in clinical trials.

ACKNOWLEDGMENTS

The authors would like to thank the CNPq, for financial assistance, the CDTN/CNEN- Centro de Desenvolvimento da Tecnologia Nuclear, Departamento de Química/UFMG and Centro de Microscopia da UFMG, for scientific support.

REFERENCES

1. D. A. Wong, V. L. Fornasier, I. MacNab, “Spinal metastases: the obvious, the occult, and the imposters”, Spine , vol. 15 , pp. 1-4 (1990). 2. P. C. Gerszten, A. Germanwala, S. A. Burton, W. C. Welch, C. Ozhasoglu, W. J. Vogel, “Combination kyphoplasty and spinal radiosurgery: a new treatment paradigm for pathological fractures”, Journal of Neurosurgery Spine , vol. 3, pp. 296-301 (2005). 3. T. S. Kaneko, V. Sehgal, H. B. Skinner, M. S. A. L. Al-Ghazi, N. S. Ramisinghani, J. H. Keyak, “Evaluation of a radiation transport modeling method for radioactive bone cement”, Physics in Medicine and Biology , vol. 55 , pp. 2451–2463 (2010). 4. M. H. Bilsky, E. Lis, J. Raizer, H. Lee, P. Boland, “The diagnosis and treatment of metastatic spinal tumor”, The Oncologist , vol. 4 , pp. 459–469 (1999). 5. J. V. Kuo, E. Cabebe, M. Al-Ghazi, I. Yakoob, N. S. Ramsinghani, R. Sanford, “Intensity- modulated radiation therapy for the spine at the University of California, Irvine”, Medical Dosimetry , vol. 27 , pp. 137-145 (2002). 6. M. L. Haley, P. C. Gerszten, D. E. Heron, Y. F. Chang, D. S. Atteberry, S. A. Burton, “Efficacy and cost-effectiveness analysis of external beam and stereotactic body radiation therapy in the treatment of spine metastases: a matched-pair analysis”, Journal of Neurosurgery Spine , vol. 14 , pp. 537-542 (2011). 7. C. Helissey, A. Levy, J. Jacob, G. Dutertre, P. E. Tardo-Dino, O. Bauduceau, L. Vedrine, C. Chargari, “External beam radiotherapy in the management of spinal metastases: review of current strategies and perspectives for highly conformal irradiation modalities”, Discovery Medicine , vol. 11 , pp. 505-11 (2011). 8. R. D. Macedo, T. P. R. Campos, “Radiovertebroplastia para tratamento de neoplasias malignas ósseas da coluna vertebral” International Nuclear Atlantic Conference – INAC , Santos-SP, pp. 1-5 (2005). 9. M. F. Silveira, T. P. R. Campos, “Avaliação radiodosimétrica através do código MCNP5 da radiosteoplastia em tumores ósseos nos membros”, Matéria (UFRJ) , vol. 12 , pp. 186- 192 (2007). 10. A. E. Hirsch, D. C. Medich, B. S. Rosenstein, C. B. Martel, J. A. Hirsch, “Radioisotopes and vertebral augmentation: dosimetric analysis of a novel approach for the treatment of malignant compression fractures”, Radiotherapy and Oncology , vol. 87 , pp. 119–126 (2008).

INAC 2011, Belo Horizonte, MG, Brazil.

11. H. Ashamalla, E. Cardoso, M. Macedon, A. Guirguis, L. Weng, S. Ali, B. Mokhtar, M. Ashamalla, N. Panigrahi, “Phase I trial of vertebral intracavitary cement and samarium (VICS): novel technique for treatment of painful vertebral metastasis”, Int. Journal of Radiation Oncology Biol. Phys. , vol. 75 , pp. 836-842 (2009). 12. L. E. Jasper, H. Deramond, J. M. Mathis, S. M. Belkoff, “Material properties of various cements for use in vertebroplasty”, Journal of Materials Science: Materials in Medicine, vol. 13 , pp. 1-5 (2002). 13. P. F. Heini, U. Berlemann, “Bone substitutes in vertebroplasty”, European Spine Journal , vol. 10 , pp. 205-213 (2001). 14. I. H. Lieberman, D. Togawa, M. M. Kayanja, “Vertebroplasty and kyphoplasty: filler materials”, The Spine Journal , vol. 5 , pp. 305-316 (2005). 15. L. Hernández, M. Gurruchaga, I. Goñi, “Injectable acrylic bone cements for vertebroplasty based on a radiopaque hydroxyapatite: formulation and rheological behavior”, Journal of Materials Science: Materials in Medicine , vol. 20 , pp. 89-97 (2009). 16. M. Komath, H. K. Varma, “Development of a fully injectable calcium phosphate cement for orthopedic and dental applications”, Bulletin of Materials Science , vol. 26 , pp. 415- 422 (2003). 17. T. J. Webster, E. A. Massa-Schlueter, J. L. Smith, E. B. Slamovich, “Osteoblast response to hydroxyapatite doped with divalent and trivalent cations”, Biomaterials , vol. 25 , pp. 2111-2121 (2004). 18. L. C. Chow, “Next generation calcium phosphate-based biomaterials”, Dental Materials Journal , vol. 28 , pp. 1-10 (2009). 19. S. V. Dorozhkin, “Bioceramics of calcium orthophosphates”, Biomaterials , vol. 31 , pp. 1465-1485 (2010). 20. M. A. B. C. Menezes, H. E. L. Palmieri, L. V. Leonel, H. A. Nalini, R. Ja ćimovi ć, “Iron Quadrangle, Brazil: Elemental concentration determined by k 0-instrumental neutron activation analysis Part I: samples”, Journal of Radioanalytical and Nuclear Chemistry , vol. 270 , pp. 111-116 (2006). 21. J. Peña, M. Vallet-Regí, “Hydroxyapatite, tricalcium phosphate and biphasic materials prepared by a liquid mix technique”, Journal of the European Ceramic Society, vol. 23 , pp. 1687-1696 (2003). 22. B. O. Fowler, “Infrared studies of apatites, vibrational assignments for calcium, strontium and barium hydroxyapatites utilizing isotopic substitution” Inorganic Chemistry , vol. 13 , pp. 194-207 (1974). 23. A. M. E. Kady, K. R. Mohamed, G. T. El-Bassyouni, “Fabrication, characterization and bioactivity evaluation of calcium pyrophosphate/polymeric biocomposites”, Ceramics International , vol. 35 , pp. 2933-2942 (2009). 24. S. Loher, W. J. Stark, M. Maciejewski, A. Baiker, S. E. Pratsinis, D. Reichardt, F. Maspero, F. Krumeich, D. Günther, “Fluoro-apatite and Calcium Phosphate Nanoparticles by Flame Synthesis”, Chemistry of Materials , vol. 17 , pp. 36-42 (2005). 25. A. Hezel, S. D. Ross, “The far infra-red spectra of some divalent pyrophosphates”, Spectrochimica Acta A , vol. 24 , pp. 131-135 (1968). 26. J. Chen, Y. Wang, X. Chen, L. Ren, C. Lai, W. He, Q. Zhang, “A simple sol-gel technique for synthesis of nanostructured hydroxyapatite, tricalcium phosphate and biphasic powders”, Materials Letters , vol. 65 , pp. 1923-1926 (2011). 27. P. Layrolle, A. Ito, T. Tateishi, “Sol-gel synthesis of amorphous calcium phosphate and sintering into microporous hydroxyapatite bioceramics”, J. Am. Ceram. Soc. , vol. 81 , pp. 1421-1428 (1998).

INAC 2011, Belo Horizonte, MG, Brazil.

28. W. L. Suchaneka, P. Shuk, K. Byrappa, R. E. Riman, K. S. TenHuisenb, V. F. Janas, “Mechanochemical–hydrothermal synthesis of carbonated apatite powders at room ”, Biomaterials , vol. 23 , pp. 699-710 (2002). 29. A. Slósarczyk, C. Paluszkiewicz, M. Gawlicki, Z. Paszkiewicz, “The FTIR spectroscopy and QXRD studies of calcium phosphate based materials produced from the powder precursors with different Ca/P ratios”, Ceramics International , vol. 23 , pp. 297-304 (1997). 30. H. Assaoudi, A. Ennaciri, “Vibrational spectra and structure of rare earth orthophosphates, weinschenkite type”, Spectrochimica Acta A , vol. 53 , pp. 895–902 (1997).

INAC 2011, Belo Horizonte, MG, Brazil.